Drug
Sar408701
Sar408701: highest development phase Phase 1, developed by Sanofi. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Sanofi
Trials
| Drug | Phase | Indication |
|---|---|---|
| SAR408701 NCT03324113 | Phase 1 | Neoplasm Malignant |
Latest
No recent events.
Follow Sar408701 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.